F. prausnitzii and Its Supernatant Increase SCFAs-producing Bacteria to Restore Gut Dysbiosis in TNBS-Induced Colitis

Youlian Zhou
Guangzhou First Municipal People's Hospital  https://orcid.org/0000-0002-7107-3288

Haoming Xu
South China University of Technology

Jing Xu
South China University of Technology

Hailan Zhao
South China University of Technology

Ye Chen
Southern Medical University

Yongjian Zhou
South China University of Technology

Yuqiang Nie (✉ eynieuquiang@scut.edu.cn)
South China University of Technology

Original article

Keywords: inflammatory bowel disease, gut microbiota, F. prausnitzii, supernatant, short chain fatty acid

DOI: https://doi.org/10.21203/rs.3.rs-88255/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

An increasing number of studies have shown that *Faecalibacterium prausnitzii* (*F. prausnitzii*) is a promising anti-inflammatory bacterium that colonizes in the gut and that gut microbiota dysbiosis plays an important role in the pathogenesis of inflammatory bowel disease (IBD). In this study, we report the gut microbiota profile of 2,4,6 trinitrobenzene sulfonic acid (TNBS)-induced colitis mice treated with *F. prausnitzii* and its supernatant on the basis of high-throughput sequencing. We interestingly found that both *F. prausnitzii* and its metabolites exerted protective effects against colitis in mice, which ameliorated gut dysbiosis, with an increase in bacterial diversity and the abundance of short-chain fatty acid (SCFA) - producing bacteria and a decrease in serum TNF-α and the abundance of Proteinbacteria, Acidobacteria, and Bacteroidetes. These findings will provide further evidence of the anti-inflammatory effect of *F. prausnitzii*, which presents therapeutic potential for IBD treatment.

Introduction

Inflammatory bowel disease (IBD) is a group of refractory digestive diseases including Crohn’s disease (CD) and ulcerative colitis (UC). At present, there is a lack of satisfactory targeted drugs and therapies for the IBD. A large proportion of patients show complications or cancer development or require surgical treatment after using 5-aminosalicylates (5-ASA), steroids, immunomodulators, biological agents and other drugs. Compared with other gastrointestinal diseases, widespread concern about IBD has been aroused because of the high cost of its treatment and high relapse rate. To date, however, the pathogenesis of IBD has not been fully elucidated. It is well known that the gut microbiota plays a substantial role in the pathogenesis of IBD. There is increasing interest in the development of microbiota-modulating therapies for IBD, such as the use of fecal microbiota transplantation (FMT), probiotics and prebiotics.

*Faecalibacterium prausnitzii* (*F. prausnitzii*), is an anaerobic bacterium that mainly exists in the ileocecal and terminal ileum. Accumulating studies have shown that the abundance of *F. prausnitzii* is significantly reduced in the stool of patients with acute IBD, especially in those with acute UC, but there is no difference in the proportion of *F. prausnitzii* between patients in IBD remission and healthy controls (Sokol et al. 2009). Decreases in the abundance of *F. prausnitzii* in the intestine are significantly related to the activity of CD (Friswell et al. 2010; Sokol et al. 2008). A reduced abundance of *F. prausnitzii* in the intestinal mucosa of CD patients is positively correlated with the degree of intestinal lesions during surgery (Sokol et al. 2008). Sokol *et al.* (Sokol et al. 2009) compared the fecal microbiota of patients with acute CD, those in CD remission and patients with UC and found that the abundance of Firmicutes [Clostridium leptum and Clostridium coccoides] and the ratio of the Firmicutes/Bacteroides phyla were reduced in the stool of patients with acute IBD and infectious enteritis. After recurrence in patients with UC, if the abundance of *F. prausnitzii* in the intestine is restored, it will be beneficial to disease remission (Varela et al. 2013). In animal models and *in vitro, F. prausnitzii* may regulate the metabolites of the gastrointestinal tract and peripheral blood to reduce the occurrence of colitis (Miquel et al. 2015). In addition to its direct anti-inflammatory effects (Friswell et al. 2010), *F. prausnitzii* improves the
permeability of the intestinal epithelium in an IBD rat model induced by dextran sodium sulfate (DSS) (Carlsson et al. 2013), which further confirms the positive protective effect of *F. prausnitzii* on IBD. While the investigation of *F. prausnitzii* has gradually become a research focus and hotspot, its mechanism in IBD is still unclear. Therefore, it is of great scientific significance and clinical value to explore the molecular mechanism of *F. prausnitzii* in IBD. In this study, we aimed to investigate the effect of *F. prausnitzii* on the gut microbiota and to evaluate its protective ability when therapeutically used in acute TNBS-induced murine colitis.

**Materials And Methods**

**Bacteria culture**

*Faecalibacterium prausnitzii* (*F. prausnitzii*, ATCC27766), kindly provided by Professor Chenggong Yu from Nanjing Medical University, was grown in LYH medium ([brain heart infusion (37 g/L), yeast extract (5 g/L), blood crystal (5 mg/L)], plus maltose (1 g/L), cellobiose (1 g/L), cysteine (0.5 g/L) at 37 °C in an anaerobic incubator (97% carbon dioxide and 3% hydrogen). According to the optical density (OD) at 600 nm, the growth curve and live bacteria count were calculated based on the absorbance value in combination with the bacterial plate count (Qiu et al. 2013; Sokol et al. 2008). The *F. prausnitzii* supernatant was collected from bacterial cultures at $1 \times 10^9$ CFU/mL.

**Animal model**

Sixty 8- to 10-week-old male mice were purchased from Guangdong Medical Laboratory Animal Center (GMLAC, Foshan, Guangdong, China). These mice were kept under SPF conditions according to relevant laws and regulations of the laboratory animal ethics committee of GMLAC.

The mice were divided into 5 groups (N = 12 per group): EtOH control (EtOH), TNBS (TNBS), TNBS + 5-ASA (TNBS + ASA), TNBS + *F. prausnitzii* (TNBS + Fp), and TNBS + *F. prausnitzii* supernatant (TNBS + SN). Four groups were induced to develop colitis via the intrarectal administration of TNBS (Sigma Aldrich), which was dissolved in 50% ethanol at a dose of 25 mg/L for administration at 0.1 mL/per mouse. Before 24 h of colitis induction, 5-ASA (Sigma, 7.5 mg/mL, 0.1 mL/10 g body weight), *F. prausnitzii* (2–4 $\times$ $10^{10}$ CFU/kg), the *F. prausnitzii* supernatant (0.1 mL/10 g body weight) and PBS (0.1 mL/10 g body weight) were administered intragastrically to the mice once, which was repeated daily for the next 7 days. The EtOH control mice received PBS orally once in the first 24 h and on each of the following 7 days and were injected with 0.1 mL of a 50% ethanol solution in the rectum once in the second day. The experiment ended 24 h after the last intervention.

**Colonic pathology**

At the end of the experiment, 6 mice were randomly selected from each group. Their fresh colon tissues were collected, washed, fixed in a 4% neutral formaldehyde solution for 24 h, and routinely dehydrated, embedded, cut into 4 µm sections, which were then stained with hematoxylin-eosin (H-E). The colonic
Histopathological score was assessed blindly using a previously published grading system (Fuss et al. 2002).

**TNF-α detection in mouse serum**

TNF-α concentrations in mouse serum were quantified with an ELISA kit (Abcam, ab100747) according to the manufacturer’s recommendations.

**Stool sampling and microbiota analysis**

Stool samples from mice were collected by stimulating the anus and immediately frozen in a -80 °C refrigerator. Stool DNA extraction was performed with the Qiagen DNA Stool MiniKit (Qiagen, Cat No.51504). PCR and 16S rRNA sequencing were conducted using a MiSeq System (Illumina, Inc.). Bioinformatic analysis was performed as previously described (Zhou et al. 2018b; Zhou et al. 2018c). For the statistical analysis, we used the unpaired Student's t-test, Wilcox test and Mann-Whitney test to compare two groups. One-way ANOVA, the Kruskal-Wallis test and Tukey's posttest were used for comparisons of three groups. The results were considered statistically significant when P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.005). All analyses were performed with Prism GraphPad 6.0 and SPSS 19.0 software.

**Results**

**F. prausnitzii and its supernatant relieve symptoms and reduce body weight and colonic inflammation in mice**

Mice became symptomatic, showing symptoms such as weight loss, loose stool, and bloody diarrhea by day 2–3 of intrarectal TNBS administration. The symptoms were significantly improved by *F. prausnitzii* and its supernatant. Compared with the control group, the mice in the TNBS model group exhibited a markedly shorter colon length. The gross observation of the bowel revealed that the intestines of the mice in the EtOH group were pink, smooth and intact, while the gut lumen of the mice from the TNBS group showed swelling, congestion, a thinner colon wall, disappearance of mucosal folds, and a shortened colon. In some segments, large amounts of loose, unshaped or bloody feces were deposited in the gut lumen. After longitudinal incision, obvious ulcers were observed, and a few of the specimens exhibited intestinal adhesions and intestinal obstruction. Most of the changes observed in the gross observation of the gut were mitigated by *F. prausnitzii* and its supernatant to some extent. Histological examination also showed that *F. prausnitzii* and its supernatant could also ameliorate mucosal inflammation and histopathologic damage compared with the TNBS model group. Compared with the TNBS model group, the serum TNF-α concentrations in *F. prausnitzii* (32.51 ± 16.41 vs. 96.55 ± 16.06) and its supernatant (39.27 ± 16.70 vs. 96.55 ± 16.06) were also significantly decreased. (Fig. 1)

**F. prausnitzii and its supernatant increase gut microbiota diversity**
Mounting evidence shows that gut microbiota dysbiosis plays a significant role in the occurrence and development of IBD. To further study the effects of *F. prausnitzii* and its supernatant on the gut microbiota in IBD, we used 16S sequencing to further clarify the differences in the gut microbiome. Our findings indicated that the microbial diversity in the TNBS model group was significantly different from that in the EtOH control group, which was generally accompanied by a decrease in the diversity (Shannon index and species rank abundance curve) of gut microbiota. Treatment with both *F. prausnitzii* and its supernatant increased the diversity of the gut microbiota, especially in the supernatant group (P < 0.05). Based on the analysis of the number of OTUs, the 5 groups shared 597 OTUs, 23 of which were unique to the EtOH control group, while 27 were unique to the TNBS model group, and 22 were unique to the TNBS + ASA group. There were 15 and 21 unique OTUs in *F. prausnitzii* and its supernatant, respectively. (Fig. 2)

**F. prausnitzii and its supernatant restore gut microbiota dysbiosis and increase the abundance of SCFA-producing bacteria**

We further explored the changes in the gut microbiota composition, as shown by the relative abundance (Fig. 3), OTU level (Fig. 4) and LefSc biomarkers (Fig. 5). Compared with the TNBS model group, treatment with both *F. prausnitzii* and its supernatant increased the abundance of Firmicutes, Cyanobacteria and Clostridiales, and decreased the abundance of Proteinbacteria, Acidobacteria, and Bacteroidetes. At the genus level, *F. prausnitzii* increased the abundance of *Butyricicoccus, Roseburia, Ruminiclostridium, Lachnospiraceae, Oscillibacter, Anaerotruncus, Ruminococcaceae, Alistipes, Rikenella, Allspirophore, Deisulfoprecotella, and Mucispirillum*, which was more obvious in the *F. prausnitzii* supernatant group than in the TNBS model group. Notably, the *Butyricicoccus, Roseburia, Lachnospiraceae, Ruminococcaceae, Rikenella*, and *Eubacterium xylanophilum* are short-chain fatty acid (SCFA) -producing bacteria.

Next, we investigated significant taxonomic shifts in the microbial community through MetaStats analysis. Compared with the TNBS model group, *F. prausnitzii* treatment significantly increased the abundance of Ruminococcaceae (P < 0.01) and decreased the abundance of Peptostreptococcaceae (P < 0.01), *Ruminococcaceae_UCG* (P < 0.05), *Terrisporobacter* (P < 0.05), and *Turicibacter* (P < 0.05). These changes were the most obvious in the *F. prausnitzii* supernatant group (TNBS + SN) and were characterized by increased the abundance of Firmicutes (P < 0.01), Clostridiales (P < 0.05), Ruminococcaceae (P < 0.05), *Clostridiales_vadinBB60* (P < 0.05), *Lachnospiraceae_NK444* (P < 0.05), *Eubacterium xylanophilum* (P < 0.05), *Lachnospiraceae_bacterium_COE1* (P < 0.05), *Blautia coccoides* (P < 0.05), and reducing the abundance of Rhizobiales (P < 0.05), Peptostreptococcaceae (P < 0.01), Phyllobacteriaceae (P < 0.05), *Ruminococcaceae_UCG-002* (P < 0.01), *Terrisporobacter* (P < 0.01), *Turicibacter* (P < 0.05), *Clostridium sensu stricto* (P < 0.05), *Phyllobacterium* (P < 0.05), *Proteus mirabilis* (P < 0.05), *Streptococcus gallolyticus* (P < 0.01), and *Porphyromonadaceae_bacterium* (P < 0.01) (Fig. 6).
Interestingly, *Lachnospiraceae*, *Ruminococcaceae*, *Blautia* and *Eubacterium xylanophilum* are also SCFAs-producing bacteria.

**Discussion**

Inflammatory bowel diseases (IBD) are multifactorial disorders characterized by a partially unclear etiology and pathogenic mechanisms including gut microbiota dysbiosis. Our previous study (Zhou et al. 2018c) showed that the fecal microbiota of humans provides promising universal and promising biomarkers for the evaluation of IBD severity and IFX treatment efficacy. The composition of the intestinal microbiome and microbial-derived metabolites seem to influence the healthy state of the host both by both regulating metabolism-related pathways and affecting the expression of different genes via epigenetic effects (De Musis et al. 2020). Based on this, it has been suggested that the gut microbiota might be a promising therapeutic target in IBD. Accumulating studies have suggested that probiotic administration is useful for IBD.

*F. prausnitzii*, a representative commensal bacterium of the Firmicutes phylum, can decompose undigested cellulose in the intestinal lumen to produce SCFAs such as butyric acid, which not only provide energy for intestinal mucosal epithelial cells, but also benefit the intestinal environment and the stability of the intestinal mucosal barrier. Sokol *et al.* (Sokol *et al.* 2009) confirmed that the administration of *F. prausnitzii* A2-165 or its supernatant significantly decreased colitis severity induced by TNBS and restored gut microbiota dysbiosis, as demonstrated by real-time quantitative PCR (qPCR) analysis. *F. prausnitzii* A2-165 also exerted anti-inflammatory effects on both cellular and colitis animal models by blocking NF-KB activation and IL-8 production (Sokol *et al.* 2009), facilitating the induction of IL-10 in human and murine dendritic cells and modulating T cell responses (Rossi *et al.* 2016). Furthermore, *F. prausnitzii* (strain A2-165) or its supernatant has been confirmed to induce a significant reduction in colitis severity by downregulating MPO, pro-inflammatory cytokines, and T-cell levels (Martin *et al.* 2014), and protecting the intestinal epithelial barrier (Carlsson *et al.* 2013; Martin *et al.* 2015) in colitis mouse models. *F. prausnitzii* (ATCC 27766) or its supernatant can also exert protective effects by inhibiting Th17 differentiation and IL-17A secretion in both DSS-induced mouse colitis (Huang *et al.* 2016) and TNBS-induced colorectal colitis in rats (Zhang *et al.* 2014; Zhang *et al.* 2019), and upregulating regulatory T cells (Qiu *et al.* 2013) and butyrate production to maintain Th17/Treg balance (Zhou *et al.* 2018a) in a colitis rat model and *in vitro*. In addition, the *F. prausnitzii* HTF-F strain and the extracellular polymeric matrix (EPM) exerted anti-inflammatory effects on the clinical parameters measured in the DSS model (Rossi *et al.* 2015).

In this study, we report the gut microbiota profile of TNBS-induced colitis mice treated with *F. prausnitzii* (ATCC 27766) and its supernatant on the basis of high-throughput sequencing, and we found that treatment with *F. prausnitzii* and its supernatant significantly improved the colitis-related symptoms, increased the gut microbial diversity and mitigated gut dysbiosis. Our previous study (Zhou *et al.* 2018c) confirmed a relative decrease in SCFA-producing bacteria, including *F. prausnitzii*, *Lachnospiraceae*, *Ruminococcaceae* and *Roseburia*, which all belong to Clostridiales within the Firmicutes phylum, in
patients with IBD. In this study, we interestingly found that the protective effects of *F. prausnitzii* and its supernatant may result from an increase in the abundance of SCFA-producing bacteria such as *Butyricicoccus, Roseburia, Lachnospiraceae, Ruminococcaceae, Rikenella, Eubacterium_xylanophilum* and *Blautia*, indicating the restoration of gut microbiota dysbiosis after *F. prausnitzii* or supernatant treatment.

SCFAs are organic fatty acids with aliphatic tails of five or fewer carbons that are mainly produced by anaerobic microorganisms fermenting indigestible carbohydrates. *In vitro* studies of human intestinal cells have shown that butyrate can promote intestinal mucosal repair and inhibit the formation of inflammatory cytokines, thereby exerting an anti-inflammatory effect (Augenlicht et al. 2002; Segain et al. 2000). Through intestinal perfusion, sodium butyrate can also promote colonic mucosal healing in TNBS-induced colitis. *In vitro* studies have shown that butyrate also exhibits antitumor effects, including the reduction of the secretion of tumor necrosis factor (TNF) in intestinal epithelial cells (Segain et al. 2000), and induction of the differentiation and apoptosis of tumor cells, thereby inhibiting tumor growth (Pryde et al. 2002). It was confirmed that butyrate-producing bacteria belong to the Firmicutes phylum, mainly including *Clostridium leptum* and *Clostridium coccoides* (Kumari et al. 2013), which are mainly represented by *Faecalibacterium prausnitzii* and *Roseburia*, respectively (Louis and Flint 2009).

In summary, this work showed that both *F. prausnitzii* and its metabolites exerted protective effects against colitis in mice, which ameliorated gut dysbiosis, with an increase in bacterial diversity and the abundance of SCFA-producing bacteria and a decrease in serum TNF-α and the abundance of Proteinbacteria, Acidobacteria, and Bacteroidetes. These findings will provide further evidence of the anti-inflammatory effect of *F. prausnitzii*, which presents therapeutic potential for IBD treatment.

**Abbreviations**

IBD, inflammatory bowel disease; TNBS, 2,4,6 TriNitroBenzene Sulfonic acid; SCFAs: short-chain fatty acids; CD, Crohn's disease; UC, ulcerative colitis; 5-ASA, five-aminosalicylates; FMT, fecal microbiota transplantation; DSS, dextran sodium sulfate; OD, optical density; CFU, colony forming unit; SN, supernatant; SPF: specific pathogen free; GMLAC: Guangdong Medical Lab Animal Center; PBS: phosphate-buffered saline; ELISA: enzyme linked immunosorbent assay; HE: hematoxylin-eosin; ANOVA, Analysis of variance; OTU, operational taxonomic unit; LDA: Linear discriminant analysis; LEfse: Linear discriminant analysis (LDA) effect size; EPM, extracellular polymeric matrix; TNF, tumor necrosis factor.

**Declarations**

**Consent for publication**

Not applicable.

**Availability of data and materials**
The data used to support the findings of this study are available from the corresponding author upon request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by the grants from the National Natural Science Foundation of China (81700487, 81871905), Guangdong Medical Science and Technology Research Fund (A2019243), Natural Science Foundation of Guangdong Province (2020A1515011000), Guangzhou Planned Project of Science and Technology (202002030293, 202002020012), and the Fundamental Research Funds for the Central Universities, SCUT (2018MS82).

**Acknowledgements**

We thank Professor Chenggong Yu and Dr. Mingming Zhang from Nanjing Medical University for kindly providing *Faecalibacterium prausnitzii* (*F. prausnitzii*, ATCC27766).

**Authors’ contributions**

YLZ conducted the study, collected the data, and wrote the manuscript; HMX conducted the mouse models; JX, HLZ, collected the data; Ye Chen, interpret the data and guide the strain culture; YQN and YJZ directed the project, and approved the final manuscript.

**Acknowledgements**

Not applicable.

**References**

1. Augenlicht LH, Mariadason JM, Wilson A, Arango D, Yang W, Heerdt BG, Velcich A (2002) Short chain fatty acids and colon cancer. The Journal of nutrition 132(12):3804S-3808S
2. Carlsson AH, Yakymenko O, Olivier I, Hakansson F, Postma E, Keita AV, Soderholm JD (2013) *Faecalibacterium prausnitzii* supernatant improves intestinal barrier function in mice DSS colitis. Scandinavian journal of gastroenterology 48(10):1136-44 doi:10.3109/00365521.2013.828773
3. De Musis C, Granata L, Dallio M, Miranda A, Gravina AG, Romano M (2020) Inflammatory Bowel Diseases: The Role of Gut Microbiota. Current pharmaceutical design 26(25):2951-2961 doi:10.2174/1381612826666200420144128
4. Friswell M, Campbell B, Rhodes J (2010) The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut and liver 4(3):295-306 doi:10.5009/gnl.2010.4.3.295
5. Fuss IJ, Boirivant M, Lacy B, Strober W (2002) The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. Journal of immunology 168(2):900-8
doi:10.4049/jimmunol.168.2.900

6. Huang XL, Zhang X, Fei XY, Chen ZG, Hao YP, Zhang S, Zhang MM, Yu YQ, Yu CG (2016) Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation. World journal of gastroenterology 22(22):5201-10
doi:10.3748/wjg.v22.i22.5201

7. Kumari R, Ahuja V, Paul J (2013) Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World journal of gastroenterology 19(22):3404-14
doi:10.3748/wjg.v19.i22.3404

8. Louis P, Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS microbiology letters 294(1):1-8 doi:10.1111/j.1574-6968.2009.01514.x

9. Martin R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, Verdu EF, Bercik P, Bermudez-Humaran LG, Langella P (2014) The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflammatory bowel diseases 20(3):417-30
doi:10.1097/01.MIB.0000440815.76627.64

10. Martin R, Miquel S, Chain F, Natividad JM, Jury J, Lu J, Sokol H, Theodorou V, Bercik P, Verdu EF, Langella P, Bermudez-Humaran LG (2015) Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC microbiology 15:67
doi:10.1186/s12866-015-0400-1

11. Miquel S, Leclerc M, Martin R, Chain F, Lenoir M, Raguideau S, Hudault S, Bridonneau C, Northen T, Bowen B, Bermudez-Humaran LG, Sokol H, Thomas M, Langella P (2015) Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio 6(2)
doi:10.1128/mBio.00300-15

12. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ (2002) The microbiology of butyrate formation in the human colon. FEMS microbiology letters 217(2):133-9

13. Qiu X, Zhang M, Yang X, Hong N, Yu C (2013) Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. Journal of Crohn's & colitis 7(11):e558-68 doi:10.1016/j.crohns.2013.04.002

14. Rossi O, Khan MT, Schwarzer M, Hudcovic T, Srutkova D, Duncan SH, Stolte EH, Kozakova H, Flint HJ, Samsom JN, Harmsen HJ, Wells JM (2015) Faecalibacterium prausnitzii Strain HTF-F and Its Extracellular Polymeric Matrix Attenuate Clinical Parameters in DSS-Induced Colitis. PloS one 10(4):e0123013 doi:10.1371/journal.pone.0123013

15. Rossi O, van Berkel LA, Chain F, Tanweer Khan M, Taverne N, Sokol H, Duncan SH, Flint HJ, Harmsen HJ, Langella P, Samsom JN, Wells JM (2016) Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific reports 6:18507 doi:10.1038/srep18507
16. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47(3):397-403

17. Sokol H, Pigneur B, Watterlot L, Lakhari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America 105(43):16731-6 doi:10.1073/pnas.0804812105

18. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Dore J (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflammatory bowel diseases 15(8):1183-9 doi:10.1002/ibd.20903

19. Varela E, Manichanh C, Gallart M, Torrejon A, Borruel N, Casellas F, Guarner F, Antolin M (2013) Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Alimentary pharmacology & therapeutics 38(2):151-61 doi:10.1111/apt.12365

20. Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, Chen H, Yu C (2014) Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PloS one 9(10):e109146 doi:10.1371/journal.pone.0109146

21. Zhang M, Zhou L, Wang Y, Dorfman RG, Tang D, Xu L, Pan Y, Zhou Q, Li Y, Yin Y, Zhao S, Wu J, Yu C (2019) Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3. Int Immunol 31(8):499-514 doi:10.1093/intimm/dxz022

22. Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, Chen X, Tang D, Xu L, Yin Y, Pan Y, Zhou Q, Zhou Y, Yu C (2018a) Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. Inflammatory bowel diseases 24(9):1926-1940 doi:10.1093/ibd/izy182

23. Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y, Nie Y (2018b) Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. Journal of cellular and molecular medicine 22(4):2263-2271 doi:10.1111/jcmm.13508

24. Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, Amir A, Gonzalez A, Tripathi A, Chen M, Wu GD, Knight R, Zhou H, Chen Y (2018c) Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems 3(1) doi:10.1128/mSystems.00188-17